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Identifying genes underlying cancer development is critical to
cancer biology and has important implications across prevention, di-
agnosis and treatment. Cancer sequencing studies aim at discovering
genes with high frequencies of somatic mutations in specific types
of cancer, as these genes are potential driving factors (drivers) for
cancer development. We introduce a hierarchical Bayesian methodol-
ogy to estimate gene-specific mutation rates and driver probabilities
from somatic mutation data and to shed light on the overall propor-
tion of drivers among sequenced genes. Our methodology applies to
different experimental designs used in practice, including one-stage,
two-stage and candidate gene designs. Also, sample sizes are typically
small relative to the rarity of individual mutations. Via a shrinkage
method borrowing strength from the whole genome in assessing indi-
vidual genes, we reinforce inference and address the selection effects
induced by multistage designs. Our simulation studies show that the
posterior driver probabilities provide a nearly unbiased false discov-
ery rate estimate. We apply our methods to pancreatic and breast
cancer data, contrast our results to previous estimates and provide
estimated proportions of drivers for these two types of cancer.
1. Introduction. We introduce a semiparametric hierarchical Bayesian
model for the analysis of somatic mutations in cancer. Our study is mo-
tivated by experiments sequencing comprehensive libraries of coding genes
in tumors and matching normal samples [Cancer Genome Atlas Research
Network (2008, 2011), Sjo¨blom et al. (2006), Greenman et al. (2007), Wood
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et al. (2007), Jones et al. (2008), Parsons et al. (2008), Kan et al. (2010)].
A main goal of these studies has been to provide lists of candidate cancer
genes, for which evidence of a role in driving carcinogenesis emerged from the
the presence of somatically acquired differences between tumor and normal
genomes. These driver genes need to be distinguished from so-called pas-
senger genes, which present somatic mutations in cancer even though these
mutations are not directly related with the tumor genesis. Statistical tools
for this task have been based on hypotheses testing theory and, in particu-
lar, on methods for controlling the false discovery rates (FDR) of reported
gene lists [Greenman et al. (2006), Wood et al. (2007), Getz et al. (2007),
Parmigiani et al. (2009), Trippa and Parmigiani (2011)]. Our goal here is
to complement this approach with methodology for deriving the probability
that a gene contributes to carcinogenesis. There are four important reasons
for this: to handle multistage designs; to remedy the severe FDR overesti-
mation resulting from one-gene-at-a-time analyses; to improve ranking and
selection of genes for subsequent analyses; and to address estimation of the
total number of cancer drivers.
First, the rarity of mutations and the cost of sequencing comprehensive
lists of genes have motivated the use of multistage designs, to balance be-
tween resource use and power in detecting cancer genes [Kraft (2006), Skol
et al. (2006), Wang and Stram (2006), Sjo¨blom et al. (2006), Parmigiani
et al. (2009)]. In these studies, genes are selected for later stages based on
results of earlier stages as well as a host of other biological considerations,
including membership in key pathways, potential for drug targeting, relia-
bility of sequencing and findings of previous sequencing studies. Kan et al.
(2010), for instance, discussed the analysis of 1507 genes selected in part on
the basis of previously published results. Methods based on p-values do not
include prediction of the final findings at completion of the first stage. This
limit, in multi-stage problems, compounds with conceptual challenges when
biological judgment is used to refine lists of candidates that are moved along
to the last stages of the study. Also, multiple hypothesis testing methods
are not designed for optimally selecting genes for subsequent stages, while
Bayesian analysis allows one to obtain the probabilities (i) that a gene is a
driver and (ii) that it will be validated in subsequent stages. Posterior driver
probabilities provide two unique advantages. Prior to a new study or stage
with a pre-specified hypothetical sample size, they allow, unlike p-values,
to assess the probability, for each gene, of finding a number of mutations
that would provide evidence of an abnormal mutation rate. After a study,
they are applicable for summarizing the study findings, irrespective of the
selection criteria used to move genes through stages.
Second, the standard inferential approach for mutation analysis is to com-
pute false discovery rates based on standard multiple testing correction,
following one-gene-at-a-time analyses such as likelihood ratio tests. This ap-
proach can lead to a severe overestimation of the FDR.
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Third, an important goal of somatic mutation analysis is to determine
genes’ mutation rates. In a typical genome-wide study, sample sizes are
small relative to the rarity of individual mutations. For example, we ex-
pect to observe no mutations for most of the genes, though estimating a
population-level mutation rate of zero would be biologically implausible.
Also, in multi-stage designs, it is important to account for possible biases
arising from selecting genes with high mutation frequencies in early stages.
Both issues can be addressed using a model-based approach for estimating
individual genes’ mutation rates by “borrowing strength” from the entire
set of mutations across the genome [Efron and Morris (1973)]. Shrinkage
affects posterior driver probabilities and mutation rates estimates, as genes
for which less information is available are pulled more strongly toward the
genome-wide average.
Fourth, the change of landscape resulting from early cancer genome projects
has posed the question of the proportion of driver genes across the genome.
Wood et al. (2007) had pointed at this question and proposed conservative
estimators applied for FDR control with empirical Bayes testing procedures.
Our methodology is designed to also provide an estimate of this proportion
with the associated statement of uncertainty.
The organization of the remaining sections is as follows. Section 2 gives
a general description of cancer somatic mutation data. Section 3 describes
our Bayesian hierarchical model. Section 4 shows the results of simulated
experiments designed to assess the improvement provided by our approach
over standard alternatives. Section 5 presents a re-analysis of two published
sequencing studies. Finally, Section 6 provides additional discussion about
our method and results.
2. Cancer somatic mutation data. We consider studies providing a col-
lection of somatic mutations from genome-wide exome sequencing of samples
of a specific tumor type. Somatic mutations can be detected by comparing
DNA sequences of tumor samples to those of their matching normal sam-
ples. Each mutation is labeled as one of a set of possible mutation types,
as in the example of Table 1. Mutations of different types are observed to
have varying overall frequencies in tumor samples. Different definitions of
mutation types may be used to suit different data structures or different
biological questions. In this paper, as in Wood et al. (2007) and Jones et al.
(2008), each mutation is classified either as a small insertion/deletion or as
one of 24 types of single nucleotide changes, defined in Table 1. For each
gene, mutation type and sample, it is important to consider the mutation
count as well as the number of nucleotides at risk for that type of mutation,
heretofore called the coverage. The coverage for a gene may be smaller than
the total base count because not all bases may be reliably sequenced.
4 DING, TRIPPA, ZHONG AND PARMIGIANI
Table 1
24 point mutation types
Mutated from Mutated to
C in CpG A – G T
G in CpG A C – T
G in GpA A C – T
C in TpC A – G T
A – C G T
Other C A – G T
Other G A C – T
T A C G –
We analyze data generated in two previous studies. The first [Jones et al.
(2008)] includes 24 tumors with matching normal tissues from patients with
pancreatic malignancies. The study sequenced 20,671 genes and found 1163
nonsynonymous somatic mutations harbored in 1007 genes. These muta-
tions were categorized by gene, mutation type and sample. The second study
[Wood et al. (2007)] considered breast cancer, and adopted a two-stage de-
sign with 11 samples in the discovery stage and 24 samples in the subsequent
validation stage. During the discovery stage, 18,190 genes were sequenced
and 1112 nonsynonymous mutations were identified in 1026 genes. During
the validation stage, these 1026 genes were sequenced in the additional 24
tumors, and 190 nonsynonymous mutations were identified in 154 genes. Mu-
tations were categorized by gene, mutation types and stage. The data, at the
gene level, include two mutation counts, one for each stage. An advantage of
performing Bayesian analyses of these data sets is that both the probability
model and the computational procedures can be straightforwardly adapted
to these designs, as well as other multi-stage designs.
3. Model. Somatic mutation counts are modeled using a Bayesian mul-
tilevel semi-parametric model. At the data level, the observed count of so-
matic mutations of type m in gene g and sample k, indicated by Xgmk , has
distribution
Xgmk ∼ Poisson(λgmkTgmk ),
(1)
g = 1, . . . ,G;m= 1, . . . ,M ;k = 1, . . . ,K,
where λgmk is the unknown mutation rate and Tgmk is the observed coverage
for the corresponding gene, mutation type and sample, that is, the number of
successfully sequenced bases in gene g and sample k, that are susceptible to a
mutation of typem. The term “coverage,” in the next-generation sequencing
literature, has a different interpretation. Here we use it consistently with
earlier studies using Sanger sequencing technology [e.g., Wood et al. (2007)].
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The binomial and multinomial distributions are often used for mutation
counts in somatic mutation analysis [Greenman et al. (2006)]. Here we use
a Poisson distribution because it is a good approximation of both those
distributions when the mutation rates are small and because it simplifies the
calculation of the posterior distributions. Our model assumes that mutations
within a single gene and among different genes occur independently of each
other conditional on mutation rates.
At the mutation rate level, we use a multiplicative random effects model
λgmk = λgαmβk,(2)
which includes a gene specific mutation rate λg, a mutation type effect αm
and a sample effect βk. The three multiplicative components have the fol-
lowing interpretation: the λg’s allow to assign each gene its own mutation
rate; the αm’s allow the rates to vary across mutation types; the βk’s al-
low different samples to have different mutation rates, a feature observed in
most data sets. We set
∏M
m=1αm = 1 and
∏K
k=1 βk = 1 to make the model
identifiable.
We propose and compare two complementary approaches, one for estimat-
ing gene-specific mutation rates and one for estimating gene-specific driver
probabilities. One of the main differences is that the first approach does not
require a reliable estimate of the passenger mutation rate while the second
does. The assumption of known passenger rates has also been used in the
previous literature [e.g., Jones et al. (2008), Cancer Genome Atlas Research
Network (2008)] for identifying driver genes with FDR methods.
To complete the multilevel model, we specify a distribution for mutation
rates across genes. We treat this distribution as unknown and estimate it
from the data with minimal distributional assumptions. Early cancer genome
studies, for example, Wood et al. (2007), have shown the existence of small
subgroups of driver genes, the so-called “mountains,” with rates of mutations
over 100-fold higher than the assumed passenger rates. In contrast, most of
the likely drivers are found to harbor mutations only in small proportions of
samples and hence are called “hills.” This motivates the use of nonparametric
modeling to mitigate the overall influence of mountains on the inference. We
use a Dirichlet Process [Ferguson (1973)] for the unknown distribution of the
mutation rates across the genome:
F ∼ Dirichlet Process(a,Exponential(γ)),
(3)
λg|F
i.i.d.
∼ F,
where a is the so-called concentration parameter and γ controls the mean
of the random distribution F , chosen to be exponential. The nonparametric
Dirichlet prior is flexible and has proven useful in several applications mod-
eling random effects distribution, as done here. See Dunson (2010) for an
extensive overview.
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We can now consider the second case, in which the main interest is to
derive driver probabilities at the gene level. Here we make the additional
assumption that for all passenger genes, λg = λ0, a known mutation rate. If
this assumption holds, the driver genes can be defined statistically as those
with mutation rates greater than λ0, because any gene whose mutations
have the ability to provide a fitness advantage to cancer cells will occur in
cancer at adjusted rates higher than λ0 when a large enough population
is considered. The word adjusted here refers to the fact that, because of
different coverage and nucleotide composition, different passengers may still
exhibit different mutation rates per nucleotide even though the baseline
mutation rate λ0 is common to all.
To derive driver probabilities, we slightly modify the model above and
include an additional hierarchical level. We use binary variables δg, one
for each gene, for distinguishing the drivers (δg = 1) from the passengers
(δg = 0). The λg is now
λg = I(δg = 0)λ0 + I(δg = 1)(λ
d
g + λ0),(4)
where λdg is the difference between the mutation rate of a putative driver λg
and the pre-specified underlying passengers rate λ0. Since δg is also unknown,
a natural choice for modeling the binary variables is the conjugate Beta-
Bernoulli prior
pi ∼ Beta(api, bpi),
(5)
δg|pi
i.i.d.
∼ Bernoulli(pi),
where pi is the unknown overall proportion of drivers among all genes. We
use a Dirichelet prior for the latent λdg’s:
F ∼ Dirichlet Process(a,Exponential(γ)),
(6)
λdg|F
i.i.d.
∼ F.
Diffuse flat prior densities are used for random vectors (α1, . . . , αM ) and
(β1, . . . , βK). We also use a Gamma hyper-prior for γ. The value of a in the
Dirichlet process is set to 1. In simulations, we considered several values of
a and performed sensitivity analyses. We observed negligible variations in
our results across prior parameterizations.
The posterior distributions of parameters from the hierarchical Bayesian
models are estimated using a Markov Chain Monte Carlo algorithm. See the
supplementary material [Ding et al. (2013)] for details.
4. Simulation study.
4.1. Scenarios. We used simulations for validating our Bayesian proce-
dure. Simulation scenarios have strong similarities with the pancreatic study
in Jones et al. (2008). We used the same set of genes and their corresponding
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coverage. We set the passenger mutation rate to λ0 = 3.68×10
−7 , a realistic
rate corresponding to the geometric mean of the estimated passenger rates
across mutation types used in Jones et al. (2008). A geometric mean was
used because of the constraint on mutation type effects, that is,
∏
αm = 1.
Next, αm’s were estimated from the data and samples effects βk’s were pro-
portional to the numbers of mutations in the 24 samples in the pancreatic
cancer data. Their products were set to 1 to satisfy the constraints. In sum-
mary, the sampling model for the passenger genes in our simulation scenario
is tailored to the data and assumptions used in Jones et al. (2008). The
mutation rates of a small set of randomly selected genes were inflated to
represent true drivers: 2% of genes were set to have mutation rate 10λ0,
1% of genes were set to have mutation rate of 30λ0 and 0.05% of genes
were set to have mutation rate 200λ0. A 200-fold increase is realistic for the
so-called “mountain” genes, while 10-fold and 30-fold increases correspond
to the “hills.” The proportions of true drivers at different mutation rates
were chosen manually to make the overall distribution of observed mutation
counts close to that observed in the pancreatic cancer data.
4.2. Results. Figure 1 shows results of mutation rate estimates from
the simulated data. Estimated λg’s of individual genes are shown in Fig-
ure 1(a) against their observed mutation counts. The average estimated
mutation rate for genes with no mutation is 3.83× 10−7, very close to the
true λ0 = 3.68×10
−7 used in the simulation, even though λ0 was not known
Fig. 1. (a) Logarithm of estimated mutation rate (λHB) against the observed number
of mutations. (b) Cumulative distribution of the logarithm of λHB with genes grouped by
their true λg’s. In (a), each point is one gene, and the Y axis levels are slightly shifted to
separate the groups. Vertical dashed lines indicate true λg’s used in the simulation. The
legend in (a) applies to both (a) and (b).
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to the estimation procedure. This suggests that the model captures the un-
derlying passenger mutation rate. Also, for genes with no mutation, there
is no separation among genes with different true mutation rates, which is
expected since there is no information to distinguish them. Estimated muta-
tion rates generally increase as the number of mutations increases, but there
are also large differences in estimated rates among genes with the same num-
ber of mutations, resulting from different sizes and nucleotide compositions
of those genes.
Figure 1(b) shows the estimated λg’s by groups defined by the true λg’s.
Each line is the cumulative distribution of the logarithms of the estimated
λg’s for one of the groups. Even among genes with 200-fold increases over the
passenger rate, two genes are not distinguishable from passengers because
they did not have any mutations in the 24 simulated samples. This illustrates
the challenges of learning gene-specific mutation rates in this type of study.
As an alternative approach to estimating mutation rates we considered the
maximum likelihood estimates (MLE) calculated for each gene separately.
We assumed the same Poisson model for the MLE. For the calculation of
the MLEs, the true parameters αm’s and βk’s were plugged in, a choice that
favors the MLEs. Figure 2 compares posterior means of λg’s obtained using
Fig. 2. Hierarchical Bayesian estimates versus maximum likelihood estimates of muta-
tion rates. Each point is a gene, labeled according to its number of mutations and colored
according to whether it is a true driver. Drivers are over-plotted or else drivers with a
single mutation would be invisible, given the large number of other genes.
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our Hierarchical Bayesian model to the MLEs. Only genes with at least one
observed mutation are shown. The differences between the two approaches
are striking. Ranking genes by estimated rates, and proceeding down the list
based on the Bayesian estimates, one does not encounter a true passenger
until position 39. On the other hand, the top two genes by MLE are both
true passengers and among the top 30 genes; only 22 are true drivers. The
behavior of the two approaches is most different for genes with a single
mutation, as expected. The hierarchical model has pulled these strongly
toward the overall genome mean, so that the genes with one mutation rank
below most of the genes with more than one mutation. For genes with two
mutations, the shrinkage is less pronounced, and for genes with 3 or more
mutations, the estimates are generally close, with the exception of a small
number of large genes who are pulled strongly, and in a nonlinear pattern,
toward smaller values.
The main difference between our hierarchical Bayesian approach and the
MLE is shrinkage. By using a mixing distribution representative of the dis-
tribution of the genes’ rates across the genome, the Bayesian approach esti-
mates each mutation rate using data from many other genes with potentially
similar rates. This underlying distribution is not considered by the MLE ap-
proach.
Figure 3 shows the posterior driver probabilities from the same simulated
data set. The true passenger mutation rate used in the simulation was used as
λ0 in the Bayesian model. Overall the results have similar patterns compared
to those of the estimated mutation rates. Figure 3(a) shows estimated driver
Fig. 3. (a) Estimated driver probability against the observed number of mutations.
(b) Cumulative distribution of the estimated driver probabilities with genes grouped by
their true λg’s. In (a), each point is one gene, and the Y axis levels are slightly shifted to
separate the groups. The legend in (a) applies to both (a) and (b).
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probabilities of all genes against their observed mutation counts. Genes with
no mutation have estimated driver probabilities close to 0 regardless of their
true mutation rates. As the number of mutations increases, the estimated
driver probabilities generally also increase. Only a small number of genes
have estimated probabilities close to 1. Figure 3(b) groups genes by their
true mutation rates to present the differences among the four groups. For
genes with true mutation rates equal to 200λ0, estimated driver probabilities
are large, except for the two genes with no observed mutation. A substantial
proportion of the genes with mutation rates equal to 10λ0 and 30λ0 have
estimated driver probabilities much larger than 0.
The estimated proportion of driver genes, pi, is 0.025 with a 90% cred-
ible interval (0.017,0.041), while the true value used in the simulation is
0.0305. We also used several different Beta distributions as priors for pi and
they all led to similar posterior estimates. Using different values as λ0 in
the model resulted in very different estimates of pi. Doubling λ0 led to an
estimated pi of 0.0065 with a 90% credible interval (0.0047,0.0087), while
reducing λ0 by half led to an estimated pi of 0.48 with a 90% credible interval
(0.37,0.59). These results show the dependence of the estimated pi on the
input parameter λ0.
We also used likelihood ratio tests (LRT) with Poisson densities to an-
alyze the simulated data. We used the true αm’s and βk’s for LRTs here.
For gene g, under the null hypothesis, λg = λ0, the total number of mu-
tations Xg =
∑
m,k(Xgmk ) follows a Poisson distribution with parameter∑
m,k αmβkTgmk . The p-value for the likelihood ratio test can be calculated
using the right-tail probability of Xg under the null hypothesis. We then
used the FDR controlling procedure from Benjamini and Hochberg (1995)
to calculate estimated FDRs from LRT p-values. To compare the results to
those from our method, we also calculated estimated FDR from Hierarchical
Bayesian estimates of the driver probabilities. True FDRs were calculated
using the true driver indicators used in the simulation. Figure 4 shows the
results from these two methods. The estimated FDRs from our hierarchical
Bayesian method are very close to the true FDRs, showed by the closeness
of the curve to the diagonal line. The estimated rates from likelihood ratio
tests are much smaller than the true rates, suggesting that they are too
conservative by as much as an order of magnitude.
The main reason for the overestimation of FDR here is that the control-
ling procedure assumes a uniform distribution of p-values from true null
tests. However, because the distribution of mutation counts for each gene
is Poisson and the mutation rate is very small under the null hypothesis,
the vast majority of true passenger genes have mutation counts of 0. The
resulting distribution of p-values from true passenger genes is very different
from a uniform distribution. This shows that our method has substantially
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Fig. 4. True FDRs and estimated FDRs from hierarchical Bayesian estimates of driver
probabilities and likelihood ratio test p-values for all genes.
better calibration and improved ability to estimate driver probabilities and
the overall proportion of driver genes compared to LRT coupled with an
FDR controlling procedure. This improvement is critical for the appropri-
ate interpretation of lists of candidate drivers and for the efficient design of
two-stage studies.
5. Cancer mutation data analysis.
5.1. Pancreatic cancer data. Figure 5 shows the estimates of mutation
rates with the pancreatic cancer data. Genes are ordered by their estimated
mutation rates and the 50 genes with the largest estimated rates are listed on
the top. The mean of estimated mutation rates for genes with no mutations
is 3.93 × 10−7, closer to the “intermediate” passenger mutation rate λ0 =
3.68× 10−7 than the “low” rate 2.07× 10−7 and the “high” rate 5.30× 10−7
provided in Jones et al. (2008). Among the top 50 genes, only a few have
90% credible intervals completely above the “intermediate” rate. Genes with
small sizes, such as CDKN2A, tend to have large credible intervals.
We also calculated maximum likelihood estimates of the mutation rates
λg for each gene with at least one observed mutation. See supplementary
material [Ding et al. (2013)] for the details of MLE calculation. The compari-
son between MLEs and hierarchical Bayesian estimates is shown in Figure 6.
The overall shape reproduces the pattern seen in the simulation study. The
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Fig. 5. Estimated mutation rates from the pancreatic cancer data. Genes are ordered
according to their estimated mutation rates (λHB). The names and 90% credible intervals
of the top 50 genes are shown.
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Fig. 6. Hierarchical Bayesian estimates versus maximum likelihood estimates of muta-
tion rates. Each point is a gene, labeled according to its number of mutations.
shrinkage effect is evident for most genes with only 1 mutation, and it is
greater for small genes. For example, the gene OSTN, with only 300 bases
sequenced, has a MLE of 5.7×10−5, the 11th highest rate, while the Bayesian
estimate is only 7.3× 10−7, much closer to the whole-genome average rate,
and is ranked 117th. On the other end, the gene PCDHGC4, with more than
52,000 bases sequenced, had a MLE of 2.2× 10−7 and a Bayesian estimate
of 3.8× 10−7, also closer to the genome average. The MLEs and Bayesian
estimates for genes with 3 or more mutations are similar.
Figure 7 shows the estimated driver probabilities using the “intermediate”
rate from Jones et al. (2008) as the passenger rate λ0 in our model. Genes
are ordered by their estimated driver probabilities and the 50 genes with
the highest driver probabilities are listed on the top. The list of the top 50
genes is very similar, though not identical, to that generated by the estimated
mutation rates. It is interesting to contrast the inferences on genes CDKN2A
and MLL3 with very different gene sizes. CDKN2A is a small gene with 206
bases sequenced, so 2 mutations are enough to produce a large estimated
mutation rate. CDKN2A is ranked higher than MLL3, which is a much
larger gene with 13,908 bases sequenced and 6 observed mutations. However,
CDKN2As credible interval is also much larger due to its small size. As a
result, the driver probability of MLL3 is close to one, while that of CDKN2A
is around 0.7, placing it far lower in the ranking.
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Fig. 7. Estimated driver probabilities from the pancreatic cancer data. Genes are ordered
according to their estimated driver probabilities (Pdriver). The names of the top 50 genes
are shown.
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The estimated proportion of driver genes, pi, is 0.038 with 90% credible
interval (0.018,0.066), corresponding to a total number of drivers of 779
with credible interval (381,1359). The large credible interval and the nu-
merous genes with driver probability around 50% highlight the challenge of
classifying individual genes using only 24 samples. However, the study pro-
vides strong evidence that the total number of drivers in pancreatic cancer
is large.
Changing input passenger mutation rate has a large effect on the estimates
of driver probabilities and on the overall proportion of drivers. Using the
“high” passenger mutation rate resulted in an estimated pi = 0.0041 with
90% credible interval (0.0016,0.0080), while using the “low” rate resulted
in an estimated pi = 0.28 with 90% credible interval (0.21,0.37). These rates
are likely to be conservative upper and lower bounds. While the posterior
driver probabilities are affected by the choice of passenger mutation rate λ0,
their relative orders are much more robust. For example, using the “high”
rate produced a list of top 50 genes which share 38 genes with the top 50 list
using the “low” rate. Also, even when using a conservative upper bound on
the passenger mutation rate, the expected number of drivers is close to 100.
The original paper analyzing the pancreas cancer data [Jones et al. (2008)]
used an empirical Bayes local FDR method of Efron and Tibshirani (2002),
constructed using the likelihood ratio test proposed in Getz et al. (2007). Fig-
ure 8 compares driver probabilities estimated using the hierarchical Bayesian
model in this paper to the probabilities estimated in Jones et al. (2008). Only
genes with 2 or more mutations are plotted in the figure. This is done so the
list of genes is roughly the same as the list of genes in the table S7 in Jones
et al. (2008). Note that the table in Jones et al. (2008) also used amplifi-
cation and deletion data, which are not used in the comparison here. The
estimates from these two methods are positively correlated. For most genes
shown in the figure, estimated probabilities using our method are lower than
those estimated using the empirical Bayes approach. The granularity of the
estimates from Jones et al. (2008) arises from the conservative steps taken
to overcome statistical and numerical difficulties of estimating a null dis-
tribution when event rates are low, and from monotonization of the FDR
estimates. Our Bayesian approach, through shrinkage, smoothness and other
features, provides a higher resolution. It also provides a different ranking.
To illustrate, the genes TTN and MUC16 are highlighted in Figure 8 on the
left. TTN has 6 mutations but also has more than 100K bases sequenced,
the most in this data set. This causes a greater discounting in the hierar-
chical Bayes approach than the MLE-based empirical Bayes approach. This
is consistent with the shrinkage pattern observed in Figure 3. The other
example is MUC16, which has 2 mutations and 40K bases sequenced, the
third most in this data set. Another factor that may account for some of
the differences in ranking is the consideration of sample effects, not used in
Jones et al. (2008).
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Fig. 8. Comparison between estimated driver probabilities from the hierarchical Bayesian
method (HB) and from the likelihood ratio test/empirical Bayes method (LRT/EB) in
Jones et al. (2008).
As another summarization of the hierarchical Bayesian results, Figure 9
shows the posterior distribution of the estimated number of mutated drivers
in each tumor sample. All samples except one have at least two mutated
drivers among all posterior simulations. The remaining one has less than
1% posterior probability of having only one mutated driver. Most samples
harbor five or more mutated drivers with high probabilities; the average
number is 12.
5.2. Breast cancer data. The breast cancer genome project [Wood et al.
(2007)] is presented here to emphasize the flexibility of the Bayesian ap-
proach in dealing with two-stage designs. The sample size was smaller than
that of the pancreatic cancer data. Because of that, the results have more
variability. The estimated mutation rates λg range from 8.6×10
−7 to 1.35×
10−4. The average mutation rate for genes with no mutation is 1.23× 10−6,
much higher than the corresponding rate in the pancreatic cancer data. This
rate is again closest to the intermediate, or “SNP-based,” passenger muta-
tion rate among the three estimation methods in Wood et al. (2007). The
estimated overall driver proportion pi varies for different passenger mutation
rates used in the model. Using “External,” “SNP-based” and “NS/S-based”
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Fig. 9. Posterior distribution of the estimated number of mutated drivers in each tumor
sample.
passenger rate estimates resulted in pi estimates of 53%, 12% and 0.02%,
respectively.
6. Discussion. We developed a hierarchical Bayesian methodology to es-
timate gene-specific mutation rates and driver probabilities as well as the
proportion of drivers among sequenced genes from somatic mutation data
in cancer.
To distinguish driver genes from passenger genes solely based on marginal
mutation rates, somewhat strong assumptions are needed. The first is that all
passenger genes have the same mutation rate. Biologically, mutation rates
can vary across different regions of genome [Wolfe, Sharp and Li (1989)]
from factors such as DNA replication timing [Wolfe, Sharp and Li (1989),
Stamatoyannopoulos et al. (2009)] and chromatin structure [Prendergast
et al. (2007), Schuster-Bo¨ckler and Lehner (2012)]. With the sample sizes
available in the data sets analyzed in this paper, it is difficult to consider
variation in passenger rates explicitly, though ongoing sequencing effort may
allow a deeper exploration of this issue in the near future.
Another key assumption is that mutations in different genes occur in-
dependently. Because of this assumption, we can estimate a gene’s driver
probability using its marginal mutation rate. In practice, it is likely that
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mutations in one gene can lead to growth advantage or disadvantage de-
pending on whether certain mutations in some other genes exist or not,
especially if these genes are in the same biological pathway. While modeling
of such interactions is possible for selected pathways [Boca et al. (2010),
Ciriello et al. (2012)], estimation of even pairwise dependencies at the gene
level across the entire genome remains challenging.
These assumptions represent a reasonable compromise between the limita-
tions of available sequencing data and the need to prioritize candidate driver
genes for further research in a model-based way. They were commonly made
in other cancer somatic mutation studies [e.g., Jones et al. (2008), Cancer
Genome Atlas Research Network (2008)]. With the development of new se-
quencing technologies and the increasing amount of cancer sequencing data,
new methodologies will be needed, likely with a more flexible set of assump-
tions.
Our model also assumes that each sample is homogeneous such that if
a mutation occurs in a gene in one sample, it occurs in all cells from that
sample. This assumption realistically models the data generated by Sanger
sequencing with strict quality control, where only mutations shared by the
majority of cells are identified. In reality, cancer samples are often heteroge-
neous: the same sample can distinct subpopulation of cancer cells at different
stages of evolution or even following from different evolutionary paths. So
a certain mutation may only present in a proportion of cells. Such infor-
mation can be obtained using deep sequencing technologies available now
[Walter et al. (2012)]. To analyze such data, an additional layer could be
incorporated into the hierarchical Bayesian models to account for the het-
erogeneity of cells in a sample. A challenge in modeling this information will
arise from the fact that mutations in different genes can have different levels
of heterogeneity.
We designed two models, one for estimating gene-specific mutation rates
and one for estimating gene-specific driver probabilities and the overall pro-
portion of drivers. Both achieved similar results in terms of separating groups
of genes with different true mutation rates in the simulation study and or-
dering the top candidate driver genes in the pancreatic and breast cancer
genomes data. While estimating driver probabilities provides a more direct
way to answer the question of distinguishing drivers from passengers, the
model does depend on the assumption that there is a single underlying pas-
senger mutation rate common to all passenger genes and requires this rate
as an input parameter.
So far, most analyses of somatic mutations rely on external estimates of
the mutation rates for passenger genes, obtained, for example, from sequenc-
ing data from noncoding regions or rates of silent mutations [Wood et al.
(2007)]. This input has a large effect on the estimated proportion of driver
genes and the overall magnitude of the driver probabilities. However, the or-
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der of top candidates is not affected substantially either in simulated or real
data. We thus recommend the use of estimated mutation rates for ranking,
selection and prediction, as the model for this estimation does not require
any assumption on the passenger mutation rate, nor does it need an esti-
mate of this rate. In either model, Bayesian modeling allows us to use these
external estimates, when available, for specifying the prior distribution.
Both models in this paper use a Dirichlet process on the unknown distribu-
tion of the gene-specific mutation rates across the genome. This assumption
can be substituted with other types of distributions, including parametric
ones. For example, we considered a log-normal distribution for mutation rate
estimation and a mixture prior with point mass at λ0 and a log-normal dis-
tribution truncated at λ0 for driver probability estimation. When we applied
these two choices to the simulated data, model fit was not as satisfactory as
that of the Dirichlet process (see supplementary material [Ding et al. (2013)]
for details), likely because there were a few genes with very high mutation
rates (the mountains) together with a much larger set of genes with moder-
ately increased mutation rates (the hills). The Log-normal distribution does
not fit this situation well, nor would most of the commonly used paramet-
ric distributions, especially if unimodal and controlled by a small number
of parameters. Thus, we strongly recommend the use of a flexible distribu-
tion, which can be estimated reliably even in relatively small studies, if the
number of genes is large.
Results provided here are but examples of many summarizations one can
produce using the MCMC output. For example, for each gene one can easily
compute the predictive probability of observing a mutation in a hypothetical
new tumor sample or new study. Another useful approach is to examine gene
sets or pathways. The model output can be used to compute the probability
that a chosen pathway is altered by one or more driver mutations in each of
the patients, as suggested in Boca et al. (2010).
In an important paper Greenman et al. (2006) provided likelihood-based
testing approaches for distinguishing drivers from passenger mutations. An
interesting aspect of their work is the modeling of both the mutation process
and the selection pressure on the tumor. They also considered the signifi-
cance of selection toward missense, nonsense and splice site mutations, and
proposed tests assessing variation in selection between functional domains.
A combination of the approach considered here with the features introduced
by Greenman et al. (2006), while well beyond the scope of this article, could
potentially be very useful.
Our methodology provides estimates of the total number of driver genes.
The early cancer genome project highlighted the importance of “hills,” or
genes that are drivers in a relatively small proportion of tumors. Increas-
ing independent evidence is accumulating to support the importance of the
hills. Hills are numerous and easy to miss in small studies, which suggests
that many more undiscovered hills may exist. Our model attempts a quan-
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tification of the size of this population based on mutation rates alone. This
quantification is difficult, whence the large credible intervals, and sensitive
to assumptions on passenger rates. Nonetheless, our method leads to the
prediction that the population is large, very likely in the hundreds, and
possibly in the thousands.
In conclusion, our models produce posterior inferences on all relevant pa-
rameters, using data generated from single, multi-stage and multiple studies,
potentially sequencing different sets of genes. We expect that these tools will
be helpful in both assessing the evidence provided by existing data and in
planning further experiments to confirm the genes’ role in cancer develop-
ment.
7. Software. An R package is freely available at http://bcb.dfci.harvard.
edu/%7Egp/software/CancerMutationMCMC/.
SUPPLEMENTARY MATERIAL
Supplementary methods and results (DOI: 10.1214/12-AOAS604SUPP;
.pdf). Additional technical details and simulation results.
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